Edition:
United States

argenx NV (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

18.86EUR
11:35am EDT
Change (% chg)

€-0.29 (-1.51%)
Prev Close
€19.15
Open
€19.10
Day's High
€19.15
Day's Low
€18.63
Volume
29,486
Avg. Vol
15,034
52-wk High
€19.85
52-wk Low
€10.15

Latest Key Developments (Source: Significant Developments)

Argenx announces full exercise to purchase additional adss
Friday, 19 May 2017 09:00am EDT 

May 19 (Reuters) - ARGENX NV :ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS.OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM OFFERING TO APPROXIMATELY $114.7 MILLION.  Full Article

Argenx NV's U.S.-listed ADSs open at $17.90 in debut vs IPO price of $17.00/ads
Thursday, 18 May 2017 10:45am EDT 

May 18 (Reuters) - :Argenx NV's U.S.-listed American Depository Shares open at $17.90 in debut on the NASDAQ versus IPO price of $17.00 per ADS.  Full Article

Argenx NV raises about $100 mln gross proceeds with Nasdaq IPO
Wednesday, 17 May 2017 09:57pm EDT 

May 17 (Reuters) - Argenx Nv :Says raises about $100 million gross proceeds with Nasdaq IPO.Says sale of 5,865,000 American Depository shares at a price to public of $17.00 per ADS.  Full Article

Argenx announces size of IPO in US increased to 5 million ADSs
Tuesday, 16 May 2017 01:00am EDT 

May 16 (Reuters) - ARGENX NV ::ARGENX ANNOUNCES SIZE OF INITIAL PUBLIC OFFERING IN THE UNITED STATES INCREASED TO 5 MILLION ADSS.  Full Article

Argenx sees U.S IPO of 3,600,000 american depositary shares
Monday, 8 May 2017 06:22am EDT 

May 8 (Reuters) - Argenx Nv : :Argenx sees U.S IPO of 3,600,000 american depositary shares .  Full Article

Argenx announces launch of proposed initial public offering in the United States
Monday, 8 May 2017 01:01am EDT 

May 8 (Reuters) - ARGENX NV : :ANNOUNCES LAUNCH OF PROPOSED INITIAL PUBLIC OFFERING IN THE UNITED STATES.INTENDS TO OFFER AND SELL 3.6 MILLION AMERICAN DEPOSITARY SHARES ("ADSS") REPRESENTING 3.6 MILLION ORDINARY SHARES IN AN INITIAL PUBLIC OFFERING IN UNITED STATES.  Full Article

Argenx Q1 total comprehensive loss widens to 8.4 million euros
Tuesday, 2 May 2017 12:04pm EDT 

May 2 (Reuters) - Argenx NV ::Q1 revenue EUR 6.7 million ($7.31 million) versus EUR 2.2 million year ago.Q1 operating income of EUR 7.2 million (March 31, 2016: EUR 2.8 million).Q1 total comprehensive loss of EUR 8.4 million (March 31, 2016: EUR 3.0 million).Q1 cash position of EUR 85.0 million (cash, cash-equivalents and current financial assets) (March 31, 2016: EUR 53.8 million).  Full Article

Argen X receives first preclinical milestone payment in Abbvie collaboration
Thursday, 13 Apr 2017 11:45am EDT 

Argen X BV : Receives first preclinical milestone payment in abbvie collaboration .Announces achievement of first of two preclinical milestones on its way to investigational new drug (IND) filing of ARGX-115, triggering a $10 million payment from Abbvie.  Full Article

Argenx to partner with Broteio Pharma to develop therapeutic antibody
Tuesday, 21 Mar 2017 02:00am EDT 

ArGEN X BV : Announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases . Differentiated antibody to address complement target . Represents latest collaboration to stem from Co's innovative access program . Granted option to license program after preclinical proof-of-concept .Co and Broteio will jointly develop complement-targeted antibody to establish preclinical proof-of-concept using argenx's proprietary suite of technologies.  Full Article

argenx FY loss widens to 21.4 million euros
Wednesday, 15 Mar 2017 02:19am EDT 

argenx : FY operating loss of EUR 21.4 million ($22.72 million) versus loss of EUR 15.6 million year ago . FY loss for the period of EUR 21.4 versus loss of EUR 15.3 million year ago . FY revenue EUR 14.7 million versus EUR 6.9 million year ago . Aims to launch in 2017 the phase2 proof-of-concept study for ARGX-113 in itp in March 2017 as well as a phase 1 healthy volunteer study with a subcutaneous formulation of ARGX-113 during the second half of the year . Cash position at end of the period is EUR 96.7 million versus EUR 42.3 million year ago . Aims to launch in 2017 the phase 2 proof-of-concept study for ARGX-110 in relapsed/refractory cutaneous TCL in March 2017 . Aims to provide in 2017 an update on the recruitment status of both the mg and the itp phase 2 clinical trials for ARGX-113 during the second half of the year . Aims to provide in 2017 an update on our phase 1/2 clinical trial in aml and the phase 2 clinical trial in ctcl for ARGX-110 during the second half of the year . Plans to report in 2017 the full data of our finalized phase 1 clinical trial for ARGX-111 during the first half of the year . Aims to announce in 2017 the launch of a novel pipeline program . Anticipates in 2017 hiring more personnel and consultants to support the steady growth over the past year . John de Koning, a former representative of the historic venture capital investors, will resign as board member.  Full Article

More From Around the Web

BRIEF-Argenx announces full exercise to purchase additional adss

* ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS